Company
Amplifier
Harnessing the potential of AMPK activation to address metabolic disease
Also known as Amplifier Therapeutics, Amplifier TX AB
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- Sweden
- Legal name
- Amplifier TX AB
Claim, correct or request removal
Record updated 28 September 2026
About
Amplifier Therapeutics, a Sweden-based biopharmaceutical company, is focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat diseases associated with aging including metabolic conditions, cardiovascular diseases, kidney diseases, and cancer.
Funding snapshot
- Total raised
- $33.2MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Series A, $33.2M2023-10-17
Funding rounds
- Series A
- $33.2M2023-10-17, Company stated
Products
- Other
- ATX-304
Loading relationship preview